In partnership with the UK Academy of Medical Sciences, the US National Academies of Sciences and Medicine and The World Academy of Sciences, the Royal Society is hosting this event as one of a three-part series of online events looking ahead to the 2023 Third International Summit on Human Genome Editing and features Javier Guzman, Director of Global Health Policy Program and Senior Policy, Fellow Center for Global Development
- Tania Bubela, Simon Fraser University
- Arafa Salim Said, Sickle Cell Disease Patients Community of Tanzania
- Adrian Towse, UK Office of Health Economics
- Ambroise Wonkam, Johns Hopkins University School of Medicine
- Javier Guzman, Center for Global Development
- Chris McCabe, Institute of Health Economics
ABOUT THE EVENT
Revolutionary gene-editing therapies for the treatment of sickle cell disease have achieved exciting results in clinical trials and can potentially cure this chronic condition that impacts around 6 million people worldwide, with sub-Saharan Africa accounting for three quarters of these cases. However, unless policy action is taken, these new technologies are likely to be unavailable, unaffordable, inaccessible, and unacceptable for patients living in low-resource settings. Join us to discuss the health system and price barriers that must be addressed to ensure future access to these innovative gene-editing therapies, including potential policy options for governments, industry, multilaterals, and other global health stakeholders.
Find out more about the event programme here. The live coverage will be streamed here.